NCT05244915
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 65 Years and older (Older Adult))
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with a diagnosis of cancer greater than 4 weeks prior to enrollment
https://ClinicalTrials.gov/show/NCT05244915